# Hiroshi Yamamoto

> Hiroshi Yamamoto is a seed investor at Smaregi (Osaka) backing Medical and Robotics. See 3 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Smaregi](https://shizune.co/investors/profile/smaregi)
- Location: Osaka, Japan
- Total investments: 3
- Last investment: Jan 2023
- Lead investor: 33%
- Last updated: Aug 2026

Hiroshi Yamamoto is a seed investor at Smaregi in Osaka focused on Medical and Robotics. Hiroshi Yamamoto - CEO @ Smaregi

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 1 | 33% |
| Robotics | 1 | 33% |
| Aerospace | 1 | 33% |
| Health Care | 1 | 33% |
| Therapeutics | 1 | 33% |

7 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 1 | 33% |
| Series B | 1 | 33% |
| Series D | 1 | 33% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Japan | 1 | 33% |
| United States | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Interstellar Technologies | Interstellar Technologies is a rocket development, manufacturing and launch service. | $29.6M | Series D | Jan 16, 2023 |  |
| Mediar Therapeutics | Mediar Therapeutics is a biotechnology company that develops antibody-based medicines and biologic therapies to address cancer, autoimmune diseases, and other serious health conditions. Its research platform focuses on engineering multi-specific antibodies and modular biologics that can engage multiple biological targets or pathways simultaneously,enabling precise modulation of immune responses. The company’s pipeline includes therapeutic candidates designed to activate or inhibit specific immune functions, with the goal of improving clinical outcomes in oncology and immune-mediated disorders. Mediar Therapeutics also works on scalable manufacturing processes and collaborates with scientific partners to advance its biologics from discovery through clinical development. Its approach integrates protein engineering, immunology, and translational research to create biologic medicines that address complex disease mechanisms. The company continues to refine its technology and expand its therapeutic programs to support future clinical and regulatory progress. | $20M | Seed | Mar 17, 2021 |  |
| Interstellar Technologies | Interstellar Technologies is a rocket development, manufacturing and launch service. | $170.1M | Series B | Jul 29, 2019 |  |

3 of 3 investments shown.

## Co-investors
- [Agent Capital](https://shizune.co/investors/profile/agent-capital) — VC Fund, 1 deal together
- [Mission BioCapital](https://shizune.co/investors/profile/bioinnovation-capital) — VC Fund, 1 deal together
- [CyberAgent](https://shizune.co/investors/profile/cyberagent-2) — VC Fund, 1 deal together
- [De Aardappeleters](https://shizune.co/investors/profile/de-aardappeleters) — VC Fund, 1 deal together
- [Hagiwara Electronics Holdings](https://shizune.co/investors/profile/hagiwara-electronics-holdings) — VC Fund, 1 deal together
- [IMV Corporation](https://shizune.co/investors/profile/imv-corporation) — VC Fund, 1 deal together

## About Smaregi

VC Fund · Osaka, Japan

Smaregi is a Data collection and analysis business.

4 contacts available at Smaregi.

| Name | Title | Profile |
| --- | --- | --- |
| Hiroshi Yamamoto | CEO | https://shizune.co/investors/profile/hiroshi-yamamoto |
| Makoto Tokuda | Director & Founder | https://shizune.co/investors/profile/tokuda-makoto |
| Mochiduki Takuya | Auditor | https://shizune.co/investors/profile/mochiduki-takuya |
| Yutaka Ohira | Outside Audit and Supervisory | https://shizune.co/investors/profile/yutaka-ohira |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Hiroshi Yamamoto invest in?

Hiroshi Yamamoto invests primarily in Medical, Robotics and Aerospace startups, most often at Seed and Series B stage. Most of the 3 investments tracked by Shizune back companies in Japan. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Hiroshi Yamamoto last invest?

The most recent investment recorded for Hiroshi Yamamoto closed in Jan 2023. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co